OBJECTIVES This study aimed to determine whether remote ischemic conditioning (RIC) initiated prior to primary percutaneous coronary intervention (PPCI) could reduce myocardial infarct (MI) size in patients presenting with ST-segment elevation myocardial infarction. BACKGROUND RIC, using transient limb ischemia and reperfusion, can protect the heart against acute ischemia-reperfusion injury. ...

Background: More than half of myocardial infracted (MI) patients have no conventional risk factors. Regarding the belief that opium addiction has a protective effect on heart diseases, addiction prevalence has unfortunately increased in recent years. This study was conducted to investigate the effect of opium addiction on patients with acute myocardial infarction. Methods: This case-control stu...

This chapter about antithrombotic therapy for acute myocardial infarction (MI) is part of the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patients' values may lead to different choices (for a full ...

INTRODUCTION There are many reports evaluating the effects of the amplitude of ST segment elevation in acute myocardial infarction with ST segment elevation (STEMI) on infarction zone and course. There are, however, few publications dealing with the effects of ST segment elevation shape in STEMI patients on their clinical course and prognosis. AIM Assessment of the rate of "tombstoning" of ST...

To cite: Inami T, Tsurumi M, Seino Y, et al. BMJ Case Rep Published online: [please include Day Month Year] doi:10.1136/ bcr-2014-204340 DESCRIPTION A 40-year-old man presented with chest pain. Eight years ago he had suffered from acute anteroseptal ST-elevation myocardial infarction (MI) and 3 years ago he stopped taking medicines including antiplatelet drugs and warfarin by himself. ECG showe...

Background—KAI-9803, a -protein kinase C inhibitor, has been shown to ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI). Methods and Results—Direct Inhibition of -Protein Kinase C Enzyme to Limit Total Infarct Size in Acute Myocardial Infarction (DELTA MI) was a “first-in-human,” dose-escalation study that evaluated the safety, toler...

BACKGROUND Patients with myocardial infarction (MI) have a high mortality. Therefore, new risk markers and predictors of an adverse outcome for MI are required. The role of hyperglycemia in the development of cardiovascular complications in MI patients is still unclear. METHODS A total of 529 consecutive patients with the diagnosis of ST-segment elevation acute coronary syndrome within 24 h o...

BACKGROUND KAI-9803, a delta-protein kinase C inhibitor, has been shown to ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI). METHODS AND RESULTS Direct Inhibition of delta-Protein Kinase C Enzyme to Limit Total Infarct Size in Acute Myocardial Infarction (DELTA MI) was a "first-in-human," dose-escalation study that evaluated the s...

Background—KAI-9803, a -protein kinase C inhibitor, has been shown to ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI). Methods and Results—Direct Inhibition of -Protein Kinase C Enzyme to Limit Total Infarct Size in Acute Myocardial Infarction (DELTA MI) was a “first-in-human,” dose-escalation study that evaluated the safety, toler...